ArticleZoonoses and public health2026
Canine Leishmaniosis in Italy: Geospatial Trends and Incidence, a Shift in Epidemiological Approach.
Article in Zoonoses and public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
introductionCanine leishmaniosis (CanL) has shown a marked geographic expansion in Italy, progressively affecting central and northern regions previously considered non-endemic. Laboratory-based prevalence estimates remain informative in well-designed surveys; however, prevalence derived from diagnostic submissions may be influenced by study design (e.g., convenience sampling and clinical bias), diagnostic performance and cut-offs, and incomplete demographic denominators, limiting representativeness and comparability.
methodsWe estimated a provincial incidence proxy for CanL during 2022-2023 by combining newly diagnosed cases from routine diagnostic submissions with canine population approximations derived from ISTAT demographic data, applying a baseline dog-to-human ratio of 1:5. Rates were expressed as cases per 10,000 dogs and provinces were classified into five predefined operational risk categories. Robustness was assessed through alternative denominator scenarios (1:4 and 1:6), a restricted registry-based regional analysis in SINAC-covered regions, and descriptive comparison with independent epidemiological, entomological, and ecological evidence.
resultsIncidence estimates revealed substantial heterogeneity across Italy, ranging from 0 to nearly 500 cases per 10,000 dogs. Overall, 49 provinces (45.4%) were classified as minimal risk, 30 (27.8%) as low risk, 21 (19.4%) as moderate risk, 4 (3.7%) as high risk, and 4 (3.7%) as very high risk. Most minimal and low-category provinces were located in northern and central Italy, whereas higher categories were predominantly observed in Southern Italy and Sicily; however, very high provinces were also identified in North-Western Italy (Liguria), notably Imperia and Savona. While absolute provincial values were sensitive to denominator assumptions, registry-based analyses in SINAC-covered regions preserved the regional ranking of incidence, supporting the framework mainly for broad spatial prioritisation rather than precise estimation of absolute burden.
conclusionsIntegrating an incidence proxy alongside prevalence provides a pragmatic surveillance tool for spatial prioritisation and risk communication under real-world constraints. The framework is most informative for identifying higher-burden areas and supporting proportionate prevention and control strategies, especially when interpreted together with registry-based restricted analyses and independent external evidence. Within a One-Health perspective, incidence-based indicators in canine surveillance can improve comparability with routinely used human notification metrics and support coordinated planning across sectors, while remaining distinct in epidemiological meaning between hosts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.